New advances in cancer therapy targeting TGF-β signaling pathways
Minyue Shou, Hanyu Zhou, Ling Ma
Abstract
Secretion of transforming growth factor β (TGF-β) is a prominent feature of cancer development and a striking way to inhibit anti-tumor immunity. Elimination effects of TGF-β have far-reaching positive implications for future immunotherapy. In their article, Petersen et al. designed hemagglutinin (HA)-tagged decoy receptors comprised of the extracellular domain of TGF-βRII (TβRII-ecto) attached to glycosylphosphatidylinositol (GPI) anchors, which resulted in a profound inhibition of TGF-β-induced SMAD phosphorylation.
Topics & Concepts
Tumor microenvironmentImmunotherapyCancer researchCytotoxic T cellCancer immunotherapyCytokineImmunologyImmunosuppressionTransforming growth factorCancerMedicineBiologyImmune systemInternal medicineBiochemistryIn vitroCancer Research and TreatmentsCancer Immunotherapy and BiomarkersCAR-T cell therapy research